Study conduct The trial was conducted from 19 May 2022 to 2 March 2026 (data cutoff date) in 23 locations in Germany. The study adhered to the Declaration of Helsinki, Council for International Orga…
Nature.com
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Read full article at Nature.com
Disclaimer: This article summary is sourced from Nature.com. HealthRankings provides this for informational purposes only. Always consult a qualified healthcare provider before making medical decisions.
More health news
NPR
Why is Michigan loosening its rules for parents wanting to exempt kids from vaccines?
Yesterday
CNN
Some hantavirus-exposed cruise ship passengers return home to finish quarantine
Yesterday
Mediafeed.co
The (heartbreaking) truth about what happens to seniors when family stops visiting
Yesterday
KSL.com